WHO Grants First Prequalification Approval for Infant-Specific Malaria Treatment
Introduction
The World Health Organization has granted prequalification approval to a novel antimalarial formulation designed specifically for newborns and infants, marking a first in the agency's history. The decision, announced on April 24, applies to the drug artemether-lumefantrine.
Main Body
The prequalification designation, as stated by the WHO, confirms that the medicine meets international standards of quality, safety, and efficacy. Artemether-lumefantrine is the first antimalarial product formulated explicitly for the youngest victims of the mosquito-borne disease. Previously, infants received treatments intended for older children, a practice that carried a higher risk of dosage errors, adverse side effects, and toxicity. The broader epidemiological context underscores the significance of this development. According to WHO data from 2024, there were an estimated 282 million malaria cases and 610,000 deaths across 80 countries. Africa accounts for 95 percent of both cases and fatalities, with children under five representing three-quarters of those deaths. The WHO noted that progress against malaria is impeded by drug resistance, insecticide resistance, diagnostic failures, and sharp reductions in foreign aid spending. The prequalification approval is expected to facilitate public sector procurement and help address a longstanding treatment gap for approximately 30 million infants born annually in malaria-endemic regions of Africa. Globally, 70 percent of countries lack regulatory systems robust enough to oversee medicines, vaccines, tests, and medical devices. The WHO prequalification program ensures that key health products for international procurement adhere to global benchmarks for quality, safety, efficacy, and performance. WHO Director-General Tedros Adhanom Ghebreyesus commented on the milestone, noting that malaria has historically caused significant harm to children and communities. He stated that new vaccines, diagnostic tests, next-generation mosquito nets, and effective medicines—including those adapted for the youngest—are contributing to a shift in the trajectory of the disease. He further asserted that ending malaria within the current generation is a realistic objective, contingent upon sustained political and financial commitment.
Conclusion
This prequalification approval represents a targeted intervention to reduce the risk of malaria-related morbidity and mortality among the most vulnerable demographic. While the measure addresses a critical treatment gap, the WHO emphasizes that continued investment and systemic improvements are necessary to sustain progress toward malaria elimination.